The global genome editing market size is expected to be worth USD 4.4 Billion in 2025. It can surge to a valuation of USD 10.22 Billion by 2032. The market is anticipated to exhibit a robust CAGR of 12.8% during the forecast period (2025-2032).  

The market growth is driven by the presence of various genetic disorders and the demand for gene editing to cure diseases at their root cause. Technological strides in CRISPR/Cas9 and TALEN for successful gene editing can augur favorably for the market.

However, the high investment costs in research and development of genome editing and the commercialization of techniques are a considerable challenge for the market.

Key Market Insights

The genome editing market is characterized by investments by venture capital firms, editing for climate resilient crops, and partnerships between pharmaceutical companies and biotechnology firms.

• By type of gene editing technique, the TALENs segment is expected to score a 25.0% share in 2025. This can be attributed to the high precision of the Transcription Activator-Like Effector Nucleases (TALENs) technique. Its high demand in cell therapy manufacturing for ultra-sensitive targets and high-end gene safety applications can drive the segment’s growth over the forecast period.
• By type of therapy, the gene therapies segment is anticipated to attain a 33% market share in 2025. The high potential for gene therapies can be attributed to the demand for rare disease treatments, regulatory validation of Casgevy (exagamglogene autotemcel) for sickle cell disease in Europe, and approval for various diseases.
• By gene editing approach, the gene knock-in approach segment is anticipated to attain a significant market share in 2025. The insertion of functional genes in stem cells using the TALEN-mediated systems for the treatment of sickle cell disease is a prime instance of the vast potential of this approach.
• By gene delivery method, the ex-vivo segment is anticipated to attain a market share above 50% in 2025. The success in CAR-T cell therapies for cancer treatment can drive the segment’s growth over the forecast period.
• By region, the Asia Pacific region is anticipated to capture at least 35% market share in 2025. This can be on the account of rapid investments into R&D by the nations of South Korea, China, and Japan. Efforts were undertaken by biotechnology companies and researchers in advancing the genome editing technology by sharing their combined knowledge. On September 11, 2024, The Association of Southeast Asian Nations (ASEAN) Committee on Science, Technology, and Innovation (COSTI) gathered participants for a workshop titled Gene Editing Regulations and Prospects in ASEAN.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/genome-editing-market

Genome Editing Market Report Coverage

Market Dynamics

The rise of theranostics or personalized medicine for the treatment of chronic diseases can drive the genome editing market growth. The approval of CRISPR therapies by government regulatory authorities can facilitate the market growth. On May 16, 2025, an infant in the U.S. was treated with CRISPR-Cas9to alter his genes for a condition called CPS1 deficiency, a recessive disorder that causes ammonia to accumulate in the blood. This can pave the way for more personalized treatments in the coming years.

Novel therapeutic solutions for gene mutations can create opportunities for the market. These could lead the way for combination therapies that combine biologics and genome editing. For instance, researchers at Osaka University, Japan, discovered a gene editing technique on July 09, 2025, that allowed mice to produce their own weight loss medication after a single injection.

Market Opportunity: Use of Genomic Techniques for Sustainable Crop Production

The use of gene-editing techniques for the production of climate-resilient crops can invite investments from private and government institutions. On May 30, 2025, the European Green Deal was gaining voice as researchers want genomic techniques to gain approval without authorization. This can be a gamechanger for farmers looking to increase their yields amid shrinking arable lands.

Market Challenge: Regulatory Uncertainty to Negatively Impact Market Growth

The lack of clarity in regulations towards genome editing can plague the efforts of researchers and biotechnology firms investing in the technology. The absence of preclinical assays and the lack of standardization of regulations across jurisdictions can limit the market growth.

Analyst’s View

• The clinical successes of gene editing techniques and approval by regulatory authorities for the treatment of rare diseases can drive the genome editing market growth.
• The ex-vivo segment is expected to generate revenue for the market owing to its safety in surgical procedures.
• Mergers and acquisitions between biopharmaceutical firms are expected to be witnessed over the forecast period. 

Recent Developments

AIRNA, a U.S. biotechnology company, raised USD 155 million in a Series B round on April 01, 2025. The fresh capital will assist the company in leading the Phase II trial on its candidate, AIR-001, for the treatment of Alpha-1 antitrypsin deficiency (AATD).

Competitor Insights

• Century Therapeutics
• Arcturus Therapeutics
• Beam Therapeutics
• Editas Medicine
• Vor Biopharm
• Intellia Therapeutics
• Caribou Biosciences
• Graphite Bio
• CRISPR Therapeutics
• Prime Medicine

Market Segmentation

• By Type of Gene Editing Technique
• CRISPR-Cas System
• TALENs
• Meganucleases
• ZFNs
• Other Techniques
• By Type of Therapy
• Cell Therapies
• Gene Therapies
• Other Therapies
• By Gene Editing Approach
• Gene Knock-Out Approaches
• Gene Knock-In Approaches
• By Gene Delivery Method
• Ex-Vivo Delivery Methods
• In-Vivo Delivery Methods

Regional Insights

• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Italy
  • Germany
  • U.K.
  • Spain
  • Russia
  • France
  • Rest of Europe
• Asia Pacific
  • South Korea
  • India
  • China
  • Japan
  • Australia
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa